Attentional Mechanisms in SCD
Vanderbilt University Medical Center · NCT06002477
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 55+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Early Phase 1
- Target enrollment
- 80
- US sites recruiting
- 1
- Study start
- June 6, 2025
- Record last updated
- June 4, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This study will use an anticholinergic pharmacological probe to examine attention network function in SCD using EEG. The overall hypothesis is that in older adults with SCD, normal cognitive performance is maintained by compensatory attention network activity, supported by enhanced cholinergic function. The investigators anticipate that SCD will be associated with greater compensatory attention network activity and that disrupting this compensatory process through anticholinergic challenge will result in a greater negative effect on attentional performance (Attention Network Test, ANT) and attention network functioning (EEG) in older adults with greater subjective cognitive concern.
Being studied: Mecamylamine Challenge; Placebo Comparator Challenge
Conditions: Subjective Cognitive Decline
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- age ≥ 55
- Montreal Cognitive Assessment (MoCA) > 25 AND Global Deterioration Scale (GDS) rating \< 3
- Non-smokers
Exclusion Criteria
- medical contraindications to the drug challenge
- primary neurological disorder (such as stroke, epilepsy, etc.)
Recruiting US locations
Vanderbilt University Medical Center
Nashville, TN 37212
Study contacts (from the official record)
- Kimberly Albert, PhD · 6159364559 · kimberly.albert@vumc.org
Similar studies in Tennessee
All healthy volunteers studies in Tennessee →- RecruitingHealthy volunteersPhase 1/Phase 2
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Xencor, Inc.
- Location
- Cordova, TN + 27 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingHealthy volunteersPhase 1/Phase 2
Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.
Sanofi
- Location
- Knoxville, TN + 15 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 1/Phase 2
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Novartis Pharmaceuticals
- Location
- Knoxville, TN + 18 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingHealthy volunteersPhase 1
A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers.
Xfibra, Inc.
- Location
- Knoxville, TN
- Eligibility basics
- Ages 18–55